Knockdown of DDX3X exacerbates HFD-induced hepatic steatosis, while further studies reveal that DDX3X ameliorates steatosis during NAFLD progression by inhibiting the mTORC1 signaling pathway (Liu P. et al., 2022). Here, DDX3X is linked to fatty liver disease.